A combination of ibrutinib and venetoclax was found to provide lasting disease remission in patients with newly diagnosed chronic lymphocytic leukemia (CLL), according to researchers at The University of Texas MD Anderson Cancer Center. Findings from the single-institution Phase II study were published today in JAMA Oncology and provide the longest follow-up data on patients treated with this drug regimen.
MD Anderson researchers have discovered a new role for the metabolic enzyme, MCAD, in glioblastoma. The enzyme prevents toxic fatty acid accumulation, in addition to its normal role in energy production, and targeting MCAD led to irreversible damage and cell death specifically in cancer cells.
The University of Texas MD Anderson Cancer Center and Mirati Therapeutics, Inc. today announced a strategic research and development collaboration to expand the evaluation of Mirati’s two investigational small molecule, potent and selective KRAS inhibitors – adagrasib (MRTX849), a G12C inhibitor in clinical development, and MRTX1133, a G12D inhibitor in preclinical development, as monotherapy and in combination with other agents – which target two of the most frequent KRAS mutations in cancer.
UCLA scientists describe a new combination therapy that suppresses the MAPK pathway by holding cancer-driving proteins in a death grip. This combination of two small molecules has the potential to treat not only BRAF mutated melanoma but also additional aggressive subtypes of cancers, including melanoma, lung, pancreatic and colon cancers that harbor common mutations in cancer genes called RAS or NF1.
Today, during the ASH Annual Meeting and Exposition, Eunice Wang, MD, Chief of Leukemia and Director of Infusion Services at Roswell Park Comprehensive Cancer Center, is presenting data on two ongoing studies incorporating new treatment options for AML.
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel targeted therapy, called POMHEX, which blocks critical metabolic pathways in cancer cells with specific genetic defects. Preclinical studies found the small-molecule enolase inhibitor to be effective in killing brain cancer cells that were missing ENO1, one of two genes encoding the enolase enzyme.
A radioisotope researcher in the Radioisotope Science and Technology Division at the Department of Energy’s Oak Ridge National Laboratory, Davern is focusing on ways to use nanoparticles — particles 100 nanometers or smaller that can have special properties — to contain those radioisotopes and deliver them directly to cancer cells, where they can decay into different isotopes that irradiate those cells.
For patients with advanced solid cancers and KRAS G12C mutations, the targeted therapy sotorasib, a KRAS G12C inhibitor, resulted in manageable toxicities and durable clinical benefits, particularly in lung and colorectal cancer, in Phase I study
Inspired by the need for new and better therapies for neurodegenerative diseases, Rutgers University researchers are exploring the link between uncontrolled inflammation within the brain and the brain’s immune cells, known as microglia, which are emerging as a promising cellular target because of the prominent role they play in brain inflammation. In APL Bioengineering, the group highlights the design considerations and benefits of creating therapeutic nanoparticles for carrying pharmacological factors directly to the sites of the microglia.
For patients with non-small cell lung cancers marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses, or tumor shrinkage, in the majority of patients in a Phase I/II trial.
In a Phase II trial led by MD Anderson researchers, a combination targeted therapy acheived a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
Patients with advanced non-small cell lung cancer (NSCLC) and the MET exon 14 (METex14) skipping mutation had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study published today in the New England Journal of Medicine and presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract 9556 – Poster 322) by researchers from The University of Texas MD Anderson Cancer Center.
The targeted therapy pralsetinib appears to have high response rates and durable activity in patients with a broad variety of tumors harboring RET gene fusions, according to results from the international Phase I/II ARROW trial, led by researchers at The University of Texas MD Anderson Cancer Center.
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.
A targeted therapy drug used for breast and kidney cancers may also extend progression-free survival for patients with advanced head and neck cancer who are at high risk for recurrence after standard treatment. Patients enrolled in a randomized phase II trial who received the mTOR inhibitor everolimus were more likely to be cancer-free a year after therapy than those who took a placebo drug, and the benefit persisted for those with mutations in their TP53 gene.
Scientists at Berkeley Lab’s Molecular Foundry have designed a biocompatible polymer that has the potential to advance photothermal therapy, a technique that deploys near-infrared light to combat antibacterial-resistant infections and cancer.
MD Anderson, Artios and ShangPharma have announced the in-licensing by Artios of a small-molecule ATR inhibitor program, developed jointly by MD Anderson and ShangPharma.